"This is changing the way we practice prostate cancer." ...
MedPage Today on MSN
Study questions use of prostate cancer hormone therapy in certain cases
Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...
If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...
“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.
Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), according to a study published online Feb 24 in ...
Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results